Eribulin in advanced breast cancer: safety, efficacy and new perspectives.

Eribulin in advanced breast cancer: safety, efficacy and new perspectives.

Future Oncol. 2017 Dec;13(30):2759-2769

Authors: Garrone O, Miraglio E, Vandone AM, Vanella P, Lingua D, Merlano MC

Abstract
Eribulin is a synthetic analog of halichondrin B belonging to microtubule-targeted agents with a distinct mechanism of inhibition of microtubule dynamics. This molecule has multiple nonmitotic effects on tumor biology, exhibiting effects on epithelial-mesenchimal transition and tumor vasculature. We review here preclinical and clinical studies on eribulin. The mitotic and nonmitotic effects together with its favorable safety profile make eribulin a unique drug with high potential in the treatment of metastatic breast cancer. The new emphasis of eribulin mechanism of action on vascular remodeling, microenvironment modifications and reversal of epithelial-mesenchimal transition paves the way to rethinking the use of the drug in an immunological perspective.

PMID: 29219017 [PubMed - in process]

http://ift.tt/2ALC3Xc